← Leaderboards
Reona Sakemura
Mayo Clinic Rochester
$561,672
Attributed
$561,672
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $219.3K · FY2022–25$250K$187.5K$125K$62.5K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$561,672 · 2
By mechanism
K99$342,360 · 1
R00$219,312 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Sean S Park$1,787,171
- Yi Lin$6,996,175
- Shaji Kunnathu Kumar$7,127,192
- Haidong Dong$5,086,281
Others in their field
Other Rising Stars on “Antigens”
- Jason Dickens · Duke University$12,259,409
- Warwick Britton · University Of Sydney$10,964,476
- Suma Babu · Massachusetts General Hospital$9,673,541
- Sabrina Paganoni · Massachusetts General Hospital$9,673,541
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Philip Felgner · University Of California-Irvine$9,134,165
Research focus
AntigensApoptosisBaseAntigen TargetingB-LymphocytesB Lymphoid MalignancyBone MarrowCancer BiologyCancer CellBioinformaticsCancer TypeCareerCar T Cell TherapyCd34 GeneCell LineCell MaturationCell PhysiologyCellsCell SurfaceCellular ImmunotherapyChemokineCancer ImmunotherapyChimeric Antigen Receptor T CellsClinic
Grant awards (3)
Targeting Cancer-Associated Fibroblasts Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy$219,312
R00 · FY2025 · CA · contact PI
Targeting Cancer-Associated Fibroblasts Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy$171,180
K99 · FY2023 · CA · contact PI
Targeting Cancer-Associated Fibroblasts Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy$171,180
K99 · FY2022 · CA · contact PI